CN Patent

CN114174288A — 用氨基乙酰丙酸合酶2(alas2)调节剂治疗的方法

Assigned to Agios Pharmaceuticals Inc · Expires 2022-03-11 · 4y expired

What this patent protects

本文描述的是式I的化合物或其药学上可接受的盐：其中环A、R 1 、R 2 、a、b和n如本文所定义。还描述了治疗患有需要治疗的障碍的受试者的方法，包括通过施用式(I)化合物或其药学上可接受的盐来抑制受试者体内的氨基乙酰丙酸合酶2(ALAS2)。特别感兴趣的障碍是血液障碍，例如卟啉症和贫血。

USPTO Abstract

本文描述的是式I的化合物或其药学上可接受的盐：其中环A、R 1 、R 2 、a、b和n如本文所定义。还描述了治疗患有需要治疗的障碍的受试者的方法，包括通过施用式(I)化合物或其药学上可接受的盐来抑制受试者体内的氨基乙酰丙酸合酶2(ALAS2)。特别感兴趣的障碍是血液障碍，例如卟啉症和贫血。

Drugs covered by this patent

Patent Metadata

Patent number
CN114174288A
Jurisdiction
CN
Classification
—
Expires
2022-03-11
Drug substance claim
No
Drug product claim
No
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.